[an error occurred while processing this directive]

Journal of Chinese Integrative Medicine ›› 2008, Vol. 6 ›› Issue (3): 253-257.doi: 10.3736/jcim20080306

• Original Clinical Research • Previous Articles     Next Articles

Efficacy of hirudin in treating immunoglobulin A nephropathy with hematuria: a randomized controlled trial

Kai-long Li(),Ya-ni He, Hong-yi Zuo, Hui-min Wang, Han-lu Ding, Ju-rong Yang   

  1. Department of Nephrology, Daping Hospital, Third Military Medical University, Chongqing 400042, China
  • Received:2007-08-15 Online:2008-03-20 Published:2008-03-15
  • Contact: KL Li E-mail:likailong1966@163.com

Objective: To investigate the curative effects and side effects of hirudin in treating immunoglobulin A nephropathy (IgAN) with hematuria and minimal proteinuria in a short-term.Methods: Two hundred and sixty-two histologically confirmed cases of IgAN with hematuria and minimal proteinuria from 1998 to 2007 were randomly divided into hirudin-treated group (peroral administration of Maixuekang capsules) and dipyridamole-treated group (peroral administration of dipyridamole). In the two groups, contrast analysis of conformation and counts of erythrocytes in urine, urine protein quantitation in 24 hours, levels of serum creatinine (Scr) and creatinine clearance rate (Ccr), blood lipid, five items of blood clotting and side effects was performed.Results: After six-month treatment, the anisotrophy rate and the counts of erythrocytes in urine, and the urine protein quantitation in 24 hours in hirudin-treated group were decreased distinctly as compared with pre-treatment (P<0.01) and dipyridamole-treated group (P<0.05). On the other hand, Ccr was increased obviously in hirudin-treated group as compared with pre-treatment and dipyridamole-treated group (P<0.01). The blood lipid was also ameliorated in hirudin-treated group, but there was no significant difference. The anticoagulation effect of hirudin was better than dipyridamole (P<0.01). Efficacy assessment showed that the total response rate, complete remission rate and predominance remission rate in hirudin-treated group were higher than those in dipyridamole-treated group. Few side effects were found in both groups, and the rate of adverse reaction in gastrointestinal tract was lower in hirudin-treated group as compared with that in dipyridamole-treated group (P<0.05).Conclusion: Compared with dipyridamole, hirudin has superiority in kidney protection and decreasing the anisotrophy rate, counts of erythrocytes in urine and the urine protein

Key words: immunoglobulin A nephropathy, hematuria, hirudins, clinical research, randomized controlled trial

CLC Number: 

  • R692.31

Table 1

Renal histopathological staging of IgAN patients in two groups [Cases (%)]"

Group n Ⅳ~Ⅴ
Hirudin-treated 166 55 (33.1%) 17 (10.2%) 81 (48.8%) 13 (7.8%)
Dipyridamole-treated 96 34 (35.4%) 9 (9.4%) 46 (47.9%) 7 (7.3%)

Table 2

Changes of conformation and counts of erythrocytes in urine and levels of Scr and Ccr in two groups before treatment and after six-month treatment ($\bar{x}$±s )"

Group n Anisotrophy rate
of uric erythrocytes (%)
Uric erythrocyte
count (cells/μl)
Scr
(μmol/L)
Ccr
(ml/min)
Hirudin-treated
Pre-treatment 166 82.4±22.7 37.5±26.2 122.6±5.7 85.0±16.7
Post-treatment 166 29.6±13.5*△△ 4.3±9.7*△△ 105.2±7.9 108.4±10.2*△△
Dipyridamole-treated
Pre-treatment 96 78.6±25.1 38.8±25.6 116.8±6.3 87.7±14.9
Post-treatment 96 66.8±28.6 30.7±27.7 114.7±19.4 92.5±18.9

Table 3

Changes of blood lipid in two groups before treatment and after six-month treatment ($\bar{x}$±s, mmol/L )"

Group n TC TG HDL LDL
Hirudin-treated
Pre-treatment 166 5.42±2.32 1.33±0.79 1.55±0.36 2.39±0.63
Post-treatment 166 4.77±1.83 1.12±0.38 1.62±0.44 2.17±0.73
Dipyridamole-treated
Pre-treatment 96 5.75±2.66 1.27±0.80 1.61±0.24 2.38±0.70
Post-treatment 96 5.03±2.48 1.25±0.77 1.60±0.25 2.22±0.79

Table 4

Changes of five items of blood clotting in two groups before treatment and after six-month treatment ($\bar{x}$±s )"

Group n PT (s) INR FIB (g/L) TT (s) APTT (s)
Hirudin-treated
Pre-treatment 166 7.88±5.47 0.62±0.14 5.78±1.03 10.57±5.77 20.88±9.66
Post-treatment 166 12.69±3.12*△△ 0.97±0.22*△△ 3.57±1.16*△△ 15.33±2.65*△△ 31.25±6.90*
Dipyridamole-treated
Pre-treatment 96 7.72±6.15 0.60±0.27 5.81±0.92 10.38±6.44 22.36±10.62
Post-treatment 96 8.68±3.25 0.66±0.18 4.99±1.03 11.12±3.47 27.70±13.41

Table 5

Curative effects in two groups after six-month treatment [Cases (%)]"

Group n CR PR Effective Failure Total response rate
Hirudin-treated 166 83 (50.0)** 57 (34.3)** 22 (13.3)** 4 (2.4)** 162 (97.6)**
Dipyridamole-treated 96 13 (13.5) 16 (16.7) 34 (35.4) 33 (34.4) 63 (65.6)

Table 6

Side effects in two groups after six-month treatment [Cases (%)]"

Group n Side effect
Spontaneous petechia
on skin and mucosa
Gingiva bleeding Alimentary tract
hemorrhage
Nausea
Hirudin-treated 166 11 (6.6%) 8 (4.8%) 5 (3.0%)* 6 (3.6%)*
Dipyridamole-treated 96 5 (5.2%) 4 (4.2%) 7 (7.3%) 8 (8.3%)
[1] Li LS, Yu YS, Wang JQ . Norms for diagnosis and treatment of IgA nephropathy[J]. Shen Zang Bing Yu Tou Xi Shen Yi Zhi Za Zhi, 2004,13(3):253-255
黎磊石, 俞雨生, 王金泉 . IgA肾病诊断及治疗规范[J]. 肾脏病与透析肾移植杂志, 2004,13(3):253-255
[2] Nie LF, Yu DJ, Sun JS , et al. Clinical data analysis of 308 cases of IgA nephropathy[J]. Zhonghua Zhong Yi Yao Za Zhi, 2005,20(2):95-97
聂莉芳, 于大君, 孙建实 , 等. 308例IgA肾病临床资料分析[J]. 中华中医药杂志, 2005,20(2):95-97
[3] Lv JC, Zhang H, Liu G , et al. A retrospective analysis of clinical and pathological characteristics of IgA nephropathy with hematuria and/or minimal proteinuria[J]. Zhonghua Shen Zang Bing Za Zhi, 2004,20(6):418-420
吕继成, 张宏, 刘刚 , 等. IgA肾病呈单纯血尿和(或)轻度蛋白尿临床病理分析[J]. 中华肾脏病杂志, 2004,20(6):418-420
[4] Dong XG, Chen YP, An ZM , et al.Treatment of IgA nephropathy based on syndrome differentiation: A report of 20 cases[J].Zhong Xi Yi Jie He Xue Bao, 2004, 2(1): 35, 48
董兴刚, 陈以平, 安增梅 , 等 .中药辨证治疗IgA肾病20例临床疗效总结[J].中西医结合学报, 2004, 2(1): 35, 48
[5] Lee SM, Rao VM, Franklin WA , et al. IgA nephropathy: morphologic predictors of progressive renal disease[J]. Hum Pathol, 1982,13(4):314-322
doi: 10.1016/S0046-8177(82)80221-9 pmid: 7076216
[6] Ye RG, Chen YS, Fang JA . Symposium summary of diagnosis and treatment of kidney diseases and efficacy standards[J]. Zhongguo Zhong Xi Yi Jie He Shen Bing Za Zhi, 2003,4(6):355-357
doi: 10.3969/j.issn.1009-587X.2003.06.025
叶任高, 陈裕盛, 方敬爱 . 肾脏病诊断与治疗及疗效标准专题讨论纪要[J]. 中国中西医结合肾病杂志, 2003,4(6):355-357
doi: 10.3969/j.issn.1009-587X.2003.06.025
[7] Szeto CC, Lai FM, To KF , et al. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria[J]. Am J Med, 2001,110(6):434-437
doi: 10.1016/S0002-9343(01)00659-3
[8] Schena FP . Immunoglobulin.A nephropathy with mild renal lesions: a call in the forest for physicians and nephrologists[J]. Am J Med, 2001,110(6):499-500
doi: 10.1016/S0002-9343(01)00684-2
[9] Wei CJ . Application and research progress of leech and hirudin in kidney diseases[J]. Zhongguo Zhong Yi Yao Ke Ji, 2001,8(2):136-137
危成筠 . 水蛭及水蛭素在肾脏病中的应用及研究进展[J]. 中国中医药科技, 2001,8(2):136-137
[10] Chen XM, Xu QH, Zhang Y , et al. Preliminary study of lepirudin in delaying chronic progressing renal injury in rats with part-nephrectomy[J]. Zhonghua Nei Ke Za Zhi, 1998,37(12):838-839
doi: 10.3760/j.issn:0578-1426.1998.12.018
陈香美, 徐启河, 张颖 , 等. 重组水蛭素延缓部分肾切除大鼠慢性进行性肾损伤的初步研究[J]. 中华内科杂志, 1998,37(12):838-839
doi: 10.3760/j.issn:0578-1426.1998.12.018
[11] Li KL, He YN, Zhang JG , et al. Retrospective analysis of hirudin in treating idiopathic membranous nephropathy[J]. Zhongguo Zhong Xi Yi Jie He Shen Bing Za, 2007,8(7):417-418
doi: 10.3969/j.issn.1009-587X.2007.07.019
李开龙, 何娅妮, 张建国 , 等. 水蛭素治疗特发性膜性肾病的回顾性分析[J]. 中国中西医结合肾病杂志, 2007,8(7):417-418
doi: 10.3969/j.issn.1009-587X.2007.07.019
[1] Jing-lin Shi, Wan-hong Miao. Effects of acupuncture on lactoferrin content in tears and tear secretion in patients suffering from dry eyes: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2012, 10(9): 1003-1008.
[2] Lu-ming Chen, Hui Yu, Da-rong Wu , Xun Hu , Lan Zheng. Investigation on response of the patient-reported outcome scale of the main-symptoms of chronic obstructive pulmonary disease complicated with pulmonary heart disease. Journal of Chinese Integrative Medicine, 2012, 10(9): 970-974.
[3] Ming T. Tan , Jian-ping Liu , Lixing Lao. Adequate application of quantitative and qualitative statistic analytic methods in acupuncture clinical trials. Journal of Chinese Integrative Medicine, 2012, 10(8): 847-852.
[4] Lu Yu, Shui-miao Lin, Ru-qian Zhou, Wei-jun Tang, Pin-xian Huang, Ying Dong, Jian Wang, Zhi-hua Yu, Jiu-lin Chen, Li Wei, San-li Xing, Hui-juan Cao, Hong-bin Zhao. Chinese herbal medicine for patients with mild to moderate Alzheimer disease based on syndrome differentiation: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2012, 10(7): 766-776.
[5] Hui Luo, Jian-ping Liu, Qing Li. Methodological issues and suggestions for improvement in randomized controlled trials of Chinese herbal medicine for recurrent miscarriage. Journal of Chinese Integrative Medicine, 2012, 10(6): 604-614.
[6] Peng Fu , Xue-qiang Huang, Ai-hong Yuan, Guang Yu, Xiao-bin Mei, Ruo-lan Cu. Effects of salvianolate combined with alprostadil and reduced glutathione on progression of chronic renal failure in patients with chronic kidney diseases: a long-term randomized controlled trial. Journal of Chinese Integrative Medicine, 2012, 10(6): 641-646.
[7] Shui-qiu Deng, Xue-nong Ouyang, Zong-yang Yu, Xi-hu Dai, Xi Chen, Fang-zheng Fang, Wen-wu Wang, Zhi-zhen Liu. Influence of Chinese herbal medicine Feitai Capsule on completion or delay of chemotherapy in patients with stage ⅢB/Ⅳ non-small-cell lung cancer: a Randomized controlled trial. Journal of Chinese Integrative Medicine, 2012, 10(6): 635-640.
[8] Ming-xing Zhao, Zhen-hua Dong, Zhong-hai Yu, Shi-yuan Xiao, Ya-ming Li . Effects of Ginkgo biloba extract in improving episodic memory of patients with mild cognitive impairment: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2012, 10(6): 628-634.
[9] Ying-chun Miao , Jin-zhou Tian , Jing Shi , Min Mao. Effects of Chinese medicine for tonifying the kidney and resolving phlegm and blood stasis in treating patients with amnestic mild cognitive impairment: A randomized, double-blind and parallel-controlled trial. Journal of Chinese Integrative Medicine, 2012, 10(4): 390-397.
[10] Xiao-hui Sun, Sheng Liu . External Chinese medical therapy for pain associated with hyperplastic disease of the breast: Study protocol of a randomized, double-blind, multicenter, controlled trial. Journal of Chinese Integrative Medicine, 2012, 10(4): 384-389.
[11] Zhu Yan-feng, Luo Hai-ming, Deng Zhong-long, Fu De-yu, Yao Wang, Dai Jian. Effects of the Chinese patent medicine, Honghua Injection, on platelet glycoprotein Ⅱb/Ⅲa receptors in patients with acute coronary syndrome: a randomized controlled trial. Journal of Chinese Integrative Medicine, 2012, 10(3): 318-323.
[12] Li Min, Yang Ming-hui, Liu Yi. Effects of Chinese herbal medicine Bushen Huoxue Granule on quality of life of patients with Parkinson disease: a randomized, double-blinded and placebo-controlled trial. Journal of Chinese Integrative Medicine, 2012, 10(3): 310-317.
[13] Paula de Sousa Fragoso Ana, de Sá Ferreira Arthur. Evaluation of the immediate effects of manual acupuncture on brachial bicep muscle function in healthy individuals and poststroke patients: a study protocol of a parallel-group randomized clinical trial. Journal of Chinese Integrative Medicine, 2012, 10(3): 303-309.
[14] Li-xin Ma, Yu-yi Wang, Xin-xue Li, Jian-ping Liu . Systematic review on methodology of randomized controlled trials of post-marketing Chinese patent drugs for treatment of type 2 diabetes. Journal of Chinese Integrative Medicine, 2012, 10(3): 279-292.
[15] Wang Yun-fei, Que Hua-fa, Xu Jie-nan, Tang Han-jun, Xiang Huan-yu, Liu Xiao-dong, Zhang Zhen, Xing Jie, Shen Liang, Shan Wei, Liu An-min, Qiu Lian-yin, Deng Da-yi, Gao Dan. Assessment of external methods of traditional Chinese medicine in patients with chronic ulcer of the lower extremities: study protocol of a multicenter, randomized, parallel-group, prospective trial. Journal of Chinese Integrative Medicine, 2012, 10(2): 166-175.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Wei-xiong Liang. Problems-solving strategies in clinical treatment guideline for traditional Chinese medicine and integrative medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 1-4
[2] Zhao-guo Li. Discussion on English translation of commonly used sentences in traditional Chinese medicine: part one. Journal of Chinese Integrative Medicine, 2008, 6(1): 107-110
[3] Jun Hu, Jian-ping Liu. Non-invasive physical treatments for chronic/recurrent headache. Journal of Chinese Integrative Medicine, 2008, 6(1): 31
[4] Xue-mei Liu, Qi-fu Huang, Yun-ling Zhang, Jin-li Lou, Hong-sheng Liu, Hong Zheng. Effects of Tribulus terrestris L. saponion on apoptosis of cortical neurons induced by hypoxia-reoxygenation in rats. Journal of Chinese Integrative Medicine, 2008, 6(1): 45-50
[5] . Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication (Chinese version, part two). Journal of Chinese Integrative Medicine, 2010, 8(11): 1001-1005
[6] Daniel Weber, Janelle M Wheat, Geoffrey M Currie. Inflammation and cancer: Tumor initiation, progression and metastasis,and Chinese botanical medicines. Journal of Chinese Integrative Medicine, 2010, 8(11): 1006-1013
[7] Hong Liu , Guo-liang Zhang, Li Shen , Zhen Zeng, Bao-luo Zhou, Cheng-hai Liu, Guang Nie . Application and evaluation of a pseudotyped virus assay for screening herbs for anti-H5Nl avian influenza virus. Journal of Chinese Integrative Medicine, 2010, 8(11): 1036-1040
[8] Zhao-guo Li . A discussion of English translation of 1995 and 1997 Chinese National Standards of Traditional Chinese Medical Terminologies for Clinical Diagnosis and Treatment. Journal of Chinese Integrative Medicine, 2010, 8(11): 1090-1096
[9] Rui Jin, Bing Zhang. A complexity analysis of Chinese herbal property theory: the multiple formations of herbal property (Part 1). Journal of Chinese Integrative Medicine, 2012, 10(11): 1198-1205
[10] Hui-min Liu, Xian-bo Wang, Yu-juan Chang, Li-li Gu. Systematic review and meta-analysis of randomized controlled trials of integrative medicine therapy for treatment of chronic severe hepatitis. Journal of Chinese Integrative Medicine, 2012, 10(11): 1211-1228
[an error occurred while processing this directive]